Cash-Payers Save on Weight-Loss Drugs, Skirting Insurance
New Orleans News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Market Forces Drive Down Prices: Americans Pay Cash for Weight-Loss Drugs
As insurance coverage for popular weight-loss drugs like Wegovy and Zepbound remains scarce, more Americans are turning to cash purchases. Competition from drug makers and compounding pharmacies has significantly reduced monthly cash prices, ranging from $199 to $449. Employers are also avoiding these meds due to potential long-term cost increases. However, patients are finding deals through online telehealth sites, comparing prices like they would for other products. Despite budget strains, many find the health benefits worthwhile. The FDA is now warning against unapproved compounded versions, while companies like Hims and Hers are partnering with Novo Nordisk for genuine drugs. This shift in the market is surprisingly lowering prices, making these drugs more accessible outside the insurance system.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/4b26f1c46032e3ab